Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 07
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
DexCom Inc
DXCM
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$83.39
-3.51
-4.04%
Ult. Agg.: Oct 6, 4:41 PM
$83.39
-3.51
-4.04%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
DexCom Financials
DexCom (DXCM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est
DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billion-$5.250 billion vs $5.224 billion estimate.
Benzinga Newsdesk
PRO
DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate
DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.61 by 14.75 percent. This is a 45.83 percent increase over earnings of $0.48 per share from the same
Benzinga Newsdesk
Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share Buyback
Vandana Singh
PRO
DexCom Affirms FY2026 Sales Guidance of $5.160B-$5.250B vs $5.230B Est
2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin, and reiterating guidance for Revenue and Non-GAAP Gross Profit Margin at the following
Benzinga Newsdesk
PRO
DexCom Q1 Adj. EPS $0.56 Beats $0.47 Estimate, Sales $1.191B Beat $1.175B Estimate
DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.47 by 19.15 percent. This is a 75 percent increase over earnings of $0.32 per share from the same period
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
